GILD - Gilead Sciences, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
81.74
+1.49 (+1.86%)
At close: 4:00PM EST

82.00 +0.26 (0.32%)
After hours: 6:53PM EST

Stock chart is not supported by your current browser
Previous Close80.25
Open80.71
Bid81.65 x 1400
Ask82.00 x 300
Day's Range80.21 - 82.07
52 Week Range63.76 - 86.27
Volume11,162,836
Avg. Volume8,291,485
Market Cap106.775B
Beta0.87
PE Ratio (TTM)9.30
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.08 (2.63%)
Ex-Dividend Date2017-12-14
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters1 hour ago

    Florida man gets prison for trading on tip about Gilead deal

    Jay Fung, of Delray Beach, was sentenced by U.S. District Judge Anne Thompson in Trenton, New Jersey, after pleading guilty in March 2016 to conspiracy to commit securities fraud, prosecutors said. The former Morgan Stanley broker, Kevin Dowd, pleaded guilty in September 2013 to a criminal conspiracy charge, and has also settled with the U.S. Securities and Exchange Commission.

  • Reuters1 hour ago

    Florida man gets prison for trading on tip about Gilead deal

    A Florida man was sentenced on Wednesday to one year in prison for engaging in insider trading based on a tip he received from an ex-Morgan Stanley broker about Gilead Sciences Inc's planned $11.2 billion purchase of Pharmasset Inc in 2011, prosecutors said. Jay Fung, of Delray Beach, was sentenced by U.S. District Judge Anne Thompson in Trenton, New Jersey, after pleading guilty in March 2016 to conspiracy to commit securities fraud, prosecutors said. The former Morgan Stanley broker, Kevin Dowd, pleaded guilty in September 2013 to a criminal conspiracy charge, and has also settled with the U.S. Securities and Exchange Commission.

  • Investopedia7 hours ago

    How a Juno Takeover Could Boost Celgene

    If Celgene acquires Juno Therapeutics, it could expand its cancer-drug pipeline, opening up new revenue streams.

  • Why Celgene's Rumored Acquisition Of Juno Actually Makes Sense
    Investor's Business Daily7 hours ago

    Why Celgene's Rumored Acquisition Of Juno Actually Makes Sense

    Celgene could comfortably spend $11 billion to acquire Juno, an analyst said Wednesday after rumors circulated that the two biotechs could be in merger talks.

  • Why Juno Therapeutics Stock Is Soaring Today
    Motley Fool9 hours ago

    Why Juno Therapeutics Stock Is Soaring Today

    The pharmaceutical industry's long-anticipated consolidation of CAR-T biotech companies may be starting.

  • Is Celgene (CELG) Looking to Take Over Juno Therapeutics?
    Zacks11 hours ago

    Is Celgene (CELG) Looking to Take Over Juno Therapeutics?

    There are reports that Celgene (CELG) is in talks to acquire Juno Therapeutics to strengthen its portfolio given the recent series of setbacks.

  • Is Gilead Sciences, Inc. a Buy in 2018?
    Motley Fool12 hours ago

    Is Gilead Sciences, Inc. a Buy in 2018?

    Focus on the future rather than the past for this big biotech.

  • See what the IHS Markit Score report has to say about Gilead Sciences Inc.
    Markit12 hours ago

    See what the IHS Markit Score report has to say about Gilead Sciences Inc.

    Gilead Sciences Inc NASDAQ/NGS:GILD

  • Barrons.comyesterday

    Gilead: Finally an Upgrade!

    Shares of Gilead Sciences (GILD) underperformed in 2017, and analysts are split on whether to get slightly more optimistic about the stock, while others argue that 2018 won't be its year either.  Count Wells Fargo's Jim Birchenough and his team among the former. Birchenough writes that he's more confident in the stability of Hepatitis C trends this year, with an expectation of trough earnings in 2019, followed by multiple expansion on growth beyond that year.

  • Can Vertex Pharmaceuticals Report Solid 2017 Net Profit Margins?
    Market Realistyesterday

    Can Vertex Pharmaceuticals Report Solid 2017 Net Profit Margins?

    Should Investors Be Interested in Vertex Pharmaceuticals in 2018? In 3Q17, Vertex Pharmaceuticals (VRTX) reported non-GAAP (generally accepted accounting principals) net profits of ~$136 million, which is a YoY (year-over-year) growth of ~216.3%, driven mainly by the rapid rise in total cystic fibrosis (or CF) drug sales. The company reported non-GAAP combined SG&A (selling, general, and administrative) and R&D (research and development) expenses of ~$334 million, which is a YoY rise of 13.2%.

  • Why Vertex Pharmaceuticals Raised Its 2017 Revenue Guidance
    Market Realistyesterday

    Why Vertex Pharmaceuticals Raised Its 2017 Revenue Guidance

    Should Investors Be Interested in Vertex Pharmaceuticals in 2018?

  • How Teva Pharmaceutical Plans to Improve Financial Profile
    Market Realistyesterday

    How Teva Pharmaceutical Plans to Improve Financial Profile

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? As we saw in the previous part of this series, Teva Pharmaceutical Industries (TEVA) is determined to pay down a considerable amount of its debt totaling $32 billion over the next few years. The company aims to achieve financial stability through improvement in operating profits and stable cash flow generation over the next few years.

  • Analyst Recommendations for Vertex Pharmaceuticals in January
    Market Realistyesterday

    Analyst Recommendations for Vertex Pharmaceuticals in January

    Should Investors Be Interested in Vertex Pharmaceuticals in 2018?Financial performance in 3Q17

  • How Teva Pharmaceutical Plans to Optimize Global Generics
    Market Realist2 days ago

    How Teva Pharmaceutical Plans to Optimize Global Generics

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate?

  • Forbes2 days ago

    Gilead, CVS And Two Other Stocks Down But Not Out

    These stocks have been wounded but should recover.

  • How Teva Pharmaceutical Is Realigning Organizational Structure
    Market Realist2 days ago

    How Teva Pharmaceutical Is Realigning Organizational Structure

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? On December 14, 2017, Teva Pharmaceutical Industries (TEVA) announced its restructuring plan to cut costs by ~$3 billion over the next two years. It expects to witness a major turnaround of its business with the implementation of this plan.

  • Teva Pharmaceutical Focusing on Per Product Operating Profits
    Market Realist2 days ago

    Teva Pharmaceutical Focusing on Per Product Operating Profits

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? Teva Pharmaceutical Industries (TEVA) has been focused on maximizing its revenues through its market-leading generics portfolio. The company, however, has been facing stiff competition in the generics market from Mylan (MYL), Gilead Sciences (GILD), and Pfizer (PFE), which has resulted in price erosion in the generics market.

  • See what the IHS Markit Score report has to say about Gilead Sciences Inc.
    Markit2 days ago

    See what the IHS Markit Score report has to say about Gilead Sciences Inc.

    Gilead Sciences Inc NASDAQ/NGS:GILD

  • Can Teva’s Debt Repayment Plan Deleverage Its Balance Sheet?
    Market Realist3 days ago

    Can Teva’s Debt Repayment Plan Deleverage Its Balance Sheet?

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? Teva Pharmaceutical Industries (TEVA) has a debt of $34 billion on its balance sheet. The company is focused on reducing its net debt obligations to optimum levels over the coming years.

  • Teva to Lose 20–25 Sites, Cut 14,000 Workers in Next 2 Years
    Market Realist5 days ago

    Teva to Lose 20–25 Sites, Cut 14,000 Workers in Next 2 Years

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? As part of its recent restructuring plan, Teva Pharmaceutical Industries (TEVA) announced a $3 billion restructuring plan in December 2017. As part of its cost-saving initiative, the company plans to shut down some of its manufacturing facilities and cut its employee base.

  • 2017 Was a Year to Forget for Gilead Sciences, Inc., but This Year Could Be Better
    Motley Fool5 days ago

    2017 Was a Year to Forget for Gilead Sciences, Inc., but This Year Could Be Better

    In the short term, the biotech's success is still tied to its HIV and HCV franchises, but keep an eye on the pipeline.

  • See what the IHS Markit Score report has to say about Gilead Sciences Inc.
    Markit5 days ago

    See what the IHS Markit Score report has to say about Gilead Sciences Inc.

    Gilead Sciences Inc NASDAQ/NGS:GILD

  • 3 Reasons Dividend-Monster Pfizer Inc. Could Explode Higher
    InvestorPlace6 days ago

    3 Reasons Dividend-Monster Pfizer Inc. Could Explode Higher

    Pfizer Inc. (NYSE:PFE) has been rather quietly churning higher. Over the last six months, Pfizer stock is up nearly 10% and it hit new highs in December. With a dividend yield of 3.75% and a low valuation, many investors are content holding shares of PFE.

  • Mavyret May Prove a Strong Growth Driver for AbbVie Going Forward
    Market Realist6 days ago

    Mavyret May Prove a Strong Growth Driver for AbbVie Going Forward

    In 3Q17, AbbVie (ABBV) reported global sales of nearly $276 million for its hepatitis C (or HCV) portfolio, which reflected a 27.7% operational fall and a 26.8% reported fall year-over-year (or YoY). The company reported HCV sales of close to $60 million from the US market in 3Q17, a YoY fall of ~19.5%. AbbVie also reported HCV sales of close to $216 million from international markets in 3Q17, a YoY fall of 29.8% on an operational basis and a fall of 28.7% on a reported basis.

  • Barrons.com6 days ago

    New Year, New Gilead? It's No Longer Just About Hepatitis C

    Gilead Sciences (GILD) is changing its stripes. BMO Capital Markets' M. Ian Somaiya, for one contends that the stock is more "intriguing" as its focus shifts away from anti-virals. Somaiya argues that more predictable HCV sales, along with a strong launch of its HIV treatment bictegravir and non-Hodgkin lymphoma drug Yescarta are crucial for Gilead's new, more diverse, identity.